JNK-Dependent cJun Phosphorylation Mitigates TGFβ- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses.


Journal

Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052

Informations de publication

Date de publication:
21 11 2019
Historique:
received: 10 09 2019
revised: 12 11 2019
accepted: 18 11 2019
entrez: 27 11 2019
pubmed: 27 11 2019
medline: 18 8 2020
Statut: epublish

Résumé

Transforming growth factor-β (TGFβ) has both tumor-suppressive and tumor-promoting effects in breast cancer. These functions are partly mediated through Smads, intracellular transcriptional effectors of TGFβ. Smads form complexes with other DNA-binding transcription factors to elicit cell-type-dependent responses. Previously, we found that the collagen invasion and migration of pre-malignant breast cancer cells in response to TGFβ and epidermal growth factor (EGF) critically depend on multiple Jun and Fos components of the activator protein (AP)-1 transcription factor complex. Here we report that the same process is negatively regulated by Jun N-terminal kinase (JNK)-dependent cJun phosphorylation. This was demonstrated by analysis of phospho-deficient, phospho-mimicking, and dimer-specific cJun mutants, and experiments employing a mutant version of the phosphatase MKP1 that specifically inhibits JNK. Hyper-phosphorylation of cJun by JNK strongly inhibited its ability to induce several Jun/Fos-regulated genes and to promote migration and invasion. These results show that MEK-AP-1 and JNK-phospho-cJun exhibit distinct pro- and anti-invasive functions, respectively, through differential regulation of Smad- and AP-1-dependent TGFβ target genes. Our findings are of importance for personalized cancer therapy, such as for patients suffering from specific types of breast tumors with activated EGF receptor-Ras or inactivated JNK pathways.

Identifiants

pubmed: 31766464
pii: cells8121481
doi: 10.3390/cells8121481
pmc: PMC6952832
pii:
doi:

Substances chimiques

JUN protein, human 0
Proto-Oncogene Proteins c-jun 0
Recombinant Proteins 0
Transcription Factor AP-1 0
Transforming Growth Factor beta 0
Epidermal Growth Factor 62229-50-9
Extracellular Signal-Regulated MAP Kinases EC 2.7.11.24

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : European Research Council
ID : 787472
Pays : International

Déclaration de conflit d'intérêts

The authors declare no conflicts of interest.

Références

Trends Cancer. 2017 Jan;3(1):56-71
pubmed: 28718426
J Cell Sci. 2005 Aug 15;118(Pt 16):3573-84
pubmed: 16105881
Trends Cell Biol. 2018 Jul;28(7):509-511
pubmed: 29778529
Sci Signal. 2016 Aug 23;9(442):ra84
pubmed: 27555661
Nature. 1988 Mar 10;332(6160):166-71
pubmed: 3347253
Nature. 2012 May 16;486(7403):400-4
pubmed: 22722201
Nat Rev Mol Cell Biol. 2018 Jul;19(7):419-435
pubmed: 29643418
Nat Genet. 1999 Mar;21(3):326-9
pubmed: 10080190
Cold Spring Harb Perspect Biol. 2017 Oct 3;9(10):
pubmed: 28246179
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
Nat Rev Mol Cell Biol. 2007 Nov;8(11):857-69
pubmed: 17895899
Sci Signal. 2015 Oct 20;8(399):re10
pubmed: 26486175
Curr Opin Cell Biol. 2007 Apr;19(2):142-9
pubmed: 17303404
EMBO J. 1993 Feb;12(2):479-87
pubmed: 8382609
J Mammary Gland Biol Neoplasia. 2011 Jun;16(2):97-108
pubmed: 21494783
Mol Cell Biol. 1998 Dec;18(12):7020-9
pubmed: 9819389
Cell Death Differ. 2015 Feb;22(2):336-50
pubmed: 25301070
Mol Cell Biol. 2009 May;29(10):2748-61
pubmed: 19289495
Genes Dev. 1998 Apr 15;12(8):1227-39
pubmed: 9553051
Microbiol Mol Biol Rev. 2016 Jul 27;80(3):793-835
pubmed: 27466283
Mol Cell. 2001 Jun;7(6):1267-78
pubmed: 11430829
Cancer Res. 2012 Jul 15;72(14):3451-6
pubmed: 22586064
Recent Pat Anticancer Drug Discov. 2009 Jan;4(1):28-35
pubmed: 19149686
Oncogene. 2007 Jan 4;26(1):1-10
pubmed: 16799638
Cell. 1995 Dec 1;83(5):753-60
pubmed: 8521492
Am J Med Sci. 2017 May;353(5):474-483
pubmed: 28502334
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17582-7
pubmed: 25422452
Oncogene. 2015 Aug 20;34(34):4421-8
pubmed: 25381818
Cold Spring Harb Perspect Biol. 2016 Oct 3;8(10):
pubmed: 27449814
Nature. 1991 Dec 12;354(6353):494-6
pubmed: 1749429
J Biol Chem. 2008 Nov 28;283(48):33437-46
pubmed: 18832382
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
Oncogene. 2013 Aug 1;32(31):3606-15
pubmed: 22926518
Sci Signal. 2019 Feb 26;12(570):
pubmed: 30808818
Nat Rev Mol Cell Biol. 2012 Oct;13(10):616-30
pubmed: 22992590
Nat Rev Cancer. 2010 Jan;10(1):65-76
pubmed: 20029425
J Biol Chem. 2001 May 11;276(19):16491-500
pubmed: 11278799
Mol Cell. 2017 Dec 21;68(6):1067-1082.e12
pubmed: 29272704
Cold Spring Harb Perspect Biol. 2017 Jan 3;9(1):
pubmed: 27836834
J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73
pubmed: 15564374
Mol Ther. 2004 Feb;9(2):209-17
pubmed: 14759805
Cell. 1992 Feb 21;68(4):699-708
pubmed: 1739975
Cold Spring Harb Perspect Biol. 2016 Aug 01;8(8):
pubmed: 27481709
Oncotarget. 2011 Mar;2(3):135-64
pubmed: 21411864
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Cancer Res. 1990 Sep 15;50(18):6075-86
pubmed: 1975513
EMBO J. 1995 Apr 18;14(8):1798-811
pubmed: 7737130
Genes Dev. 2011 Mar 15;25(6):634-45
pubmed: 21406557
Oncogene. 2018 Nov;37(48):6195-6211
pubmed: 30002444
Nature. 1998 Aug 27;394(6696):909-13
pubmed: 9732876
Am J Pathol. 1996 Jan;148(1):313-9
pubmed: 8546221
Cell Rep. 2014 Nov 20;9(4):1361-74
pubmed: 25456131
Science. 1997 Jan 17;275(5298):400-2
pubmed: 8994040
Proc Natl Acad Sci U S A. 2013 Mar 26;110(13):5139-44
pubmed: 23483055
Cell Signal. 2010 Jun;22(6):894-9
pubmed: 20060892
Nucleic Acids Res. 2018 Feb 16;46(3):1180-1195
pubmed: 29186616
Cold Spring Harb Perspect Biol. 2017 Apr 3;9(4):
pubmed: 27920038
Oncogene. 1995 Jul 20;11(2):365-76
pubmed: 7624151
Nat Rev Cancer. 2003 Nov;3(11):859-68
pubmed: 14668816
Cell Tissue Res. 2012 Jan;347(1):37-49
pubmed: 21618142
Nature. 2005 Sep 8;437(7056):281-5
pubmed: 16007074
Curr Opin Cell Biol. 2018 Apr;51:1-7
pubmed: 29149681
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6686-91
pubmed: 11390996
Nat Rev Cancer. 2009 Aug;9(8):537-49
pubmed: 19629069
Cancer Cell. 2013 Sep 9;24(3):347-64
pubmed: 24029232
Oncogene. 2001 Apr 30;20(19):2390-400
pubmed: 11402335
Cell. 1988 Dec 2;55(5):875-85
pubmed: 3142689
J Clin Invest. 2013 Mar;123(3):1348-58
pubmed: 23391723
Mol Cell Biol. 2009 Jan;29(1):172-86
pubmed: 18955504
Oncogene. 1999 Apr 8;18(14):2311-21
pubmed: 10327051
EMBO J. 1993 Mar;12(3):1005-12
pubmed: 8384549
Cancer Res. 2012 Jan 15;72(2):472-81
pubmed: 22127926
Breast Cancer Res. 2012 Feb 08;14(1):204
pubmed: 22315972
Breast Cancer Res Treat. 2011 Aug;128(3):657-66
pubmed: 20821046
Nature. 2012 Apr 04;486(7403):395-9
pubmed: 22495314
Nature. 2012 Jun 10;486(7403):353-60
pubmed: 22722193
EMBO J. 2003 Jul 15;22(14):3686-95
pubmed: 12853483
Cell. 2012 Nov 21;151(5):937-50
pubmed: 23178117
J Neurosci. 1998 Jan 15;18(2):751-62
pubmed: 9425017
EMBO J. 1995 May 1;14(9):2014-9
pubmed: 7744008
Cell Death Differ. 2016 Apr;23(4):576-82
pubmed: 26470729
Mol Endocrinol. 2008 Aug;22(8):1767-80
pubmed: 18535250
Nature. 1991 May 9;351(6322):122-7
pubmed: 1903181
Nature. 1991 Oct 17;353(6345):670-4
pubmed: 1922387
Genes Dev. 1992 Sep;6(9):1799-809
pubmed: 1516834
Stem Cells. 2009 Sep;27(9):2059-68
pubmed: 19544473
Cell Res. 2018 Jul;28(7):719-729
pubmed: 29795445
Oncogene. 2005 Nov 3;24(48):7135-44
pubmed: 16044158
Oncogene. 2005 Feb 17;24(8):1434-44
pubmed: 15608675

Auteurs

Anders Sundqvist (A)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.

Oleksandr Voytyuk (O)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.

Mohamed Hamdi (M)

Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Present address: Department of Oncogenomics, Amsterdam University Medical Centers, 1105 AZ Amsterdam, The Netherlands.

Herman E Popeijus (HE)

Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
Present address: Department of Nutrition and Movement Sciences, NUTRIM School for Nutrition and Translational Research in Metabolism, Maastricht University, 6200 MD Maastricht, The Netherlands.

Corina Bijlsma- van der Burgt (CB)

Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

Josephine Janssen (J)

Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

John W M Martens (JWM)

Department of Medical Oncology, Erasmus MC Cancer Institute, Erasmus University Medical Center, 3000 CA Rotterdam, The Netherlands.

Aristidis Moustakas (A)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.

Carl-Henrik Heldin (CH)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.

Peter Ten Dijke (P)

Department of Medical Biochemistry and Microbiology, Science for Life Laboratory, Uppsala University, Box 582, SE-751 23 Uppsala, Sweden.
Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

Hans van Dam (H)

Department of Cell and Chemical Biology and Oncode Institute, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH